| Title: | AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965 |
| Authors: | Dite, TA Langendorf, CG Hoque, A Galic, S Rebello, RJ Ovens, AJ Lindqvist, LM Ngoei, KRW Ling, NXY Furic, L Kemp, BE Scott, JW Oakhill, JS |
| Issue Year: | 2018 |
| Publisher | AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC |
| Series | J. Biol. Chem.: |
| Abstract | Inhibition of the metabolic regulator AMP-activated protein kinase (AMPK) is increasingly being investigated for its therapeutic potential in diseases where AMPK hyperactivity results in poor prognoses, as in established cancers and neurodegeneration. However, AMPK-inhibitory tool compounds are largely limited to compound C, which has a poor selectivity profile. Here we identify the pyrimidine derivative SBI-0206965 as a direct AMPK inhibitor. SBI-0206965 inhibits AMPK with 40-fold greater potency and markedly lower kinase promiscuity than compound C and inhibits cellular AMPK signaling. Biochemical characterization reveals that SBI-0206965 is a mixed-type inhibitor. A co-crystal structure of the AMPK kinase domain/SBI-0206965 complex shows that the drug occupies a pocket that partially overlaps the ATP active site in a type IIb inhibitor manner. SBI-0206965 has utility as a tool compound for investigating physiological roles for AMPK and provides fresh impetus to small-molecule AMPK inhibitor therapeutic development. |
| URI: | https://publications.svi.edu.au/publications/4470 |
| Other Identifiers | 10.1074/jbc.RA118.003547 |
| Publication type | Article |